ReviewClinical cardiology2008
Current and future status of beta-blockers in the treatment of hypertension.
Review in Clinical cardiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021Pooled it
- Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.Pharmacotherapy · 2014Trial
- One Molecule, Many Faces: Repositioning Cardiovascular Agents for Advanced Wound Healing.Molecules (Basel, Switzerland) · 2024Review
- Etiological Diagnosis and Personalized Therapy for Hypertension: A Hypothesis of the REASOH Classification.Journal of personalized medicine · 2023Review
- Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder.International journal of molecular sciences · 2022Review
- Acute Myocardial Infarction and Daylight Saving Time Transitions: Is There a Risk?Clocks & sleep · 2021Article
- Dispersive Solid Phase Extraction Using Magnetic Nanoparticles Performed in a Narrow-Bored Tube for Extraction of Atorvastatin, Losartan, and Valsartan in Plasma.Advanced pharmaceutical bulletin · 2019Article
- Control of hypertension in the critically ill: a pathophysiological approach.Annals of intensive care · 2013Article
- Article
- Effects of β-adrenoceptor antagonists on alcohol drinking by alcohol-dependent rats.Psychopharmacology · 2010Article
- Change in mRNA Expression after Atenolol, a Beta-adrenergic Receptor Antagonist and Association with Pharmacological Response.Archives of drug information · 2009Article
- Cardiovascular response to beta-adrenergic blockade or activation in 23 inbred mouse strains.PloS one · 2009Article
- Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.Expert review of cardiovascular therapy · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta-adrenergic receptor blockers (beta-blockers) are effective and safe antihypertensive drugs, and have been recommended as first-line therapy for hypertension by all Joint National Committees (JNCs) for the prevention, detection, evaluation, and treatment of high blood pressure (BP) from the first to the last (JNC-7) in 2003. However, recently questions have been raised by several investigators regarding the antihypertensive effectiveness and safety of these drugs. The Medline literature on this subject was searched and pertinent studies were retrieved. Other pertinent references from existing publications were retrieved and analyzed up to 2007. Additionally, a historical perspective on the discovery of beta-blockers and their mechanism of action is given. Most of the reviewed short-term and long-term clinical trials demonstrate an effective and safe antihypertensive pattern for the beta-blockers. The weaknesses identified include the adverse effect of older beta-blockers on glucose control and stroke protection, especially in older persons. These adverse effects are attributed to their mechanism of action and BP effectiveness. On the basis of the evidence presented, beta-blockers are effective and safe antihypertensive drugs and should still be recommended as first-line therapy in most uncomplicated hypertensive patients, either alone or in combination with other drugs. There are reservations regarding their administration to diabetic and older hypertensive patients. However, when compelling indications for their use exist, they should not be withheld.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.